Teva Pharma Files 8-K with 2023 Segment Financials
Ticker: TEVJF · Form: 8-K · Filed: Apr 18, 2024 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financials, segment-reporting, exhibits
Related Tickers: TEVA
TL;DR
Teva dropped its 2023 segment financials, check out how International, US, Europe, and Canada performed.
AI Summary
Teva Pharmaceutical Industries Ltd. filed an 8-K on April 18, 2024, to report financial statements and exhibits. The filing includes segment information for the year ended December 31, 2023, detailing performance across its International Markets, United States, Europe, and Canada segments, as well as specific product lines like Copaxone, Bendeka and Treanda, Austedo, Ajovy, and Generic Products within Canada.
Why It Matters
This filing provides investors with updated financial segment data for Teva Pharmaceutical Industries Ltd., crucial for understanding the performance and strategic focus of different geographical regions and product categories.
Risk Assessment
Risk Level: low — This is a routine financial filing with no new material events or disclosures that would inherently increase risk.
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Filer
- 0001193125-24-100771 (filing_id) — Accession Number
- 20240418 (date) — Filing Date
- 2023-12-31 (date) — Fiscal Year End
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits for Teva Pharmaceutical Industries Ltd.
What fiscal period does the segment information cover?
The segment information provided in the filing covers the fiscal year ended December 31, 2023.
Which geographical segments are detailed in the filing?
The filing details segments for International Markets, United States, Europe, and Canada.
Are specific product lines mentioned within the Canadian segment?
Yes, specific product lines mentioned within the Canadian segment include Copaxone, Bendeka and Treanda, Austedo, Ajovy, and Generic Products.
What is Teva Pharmaceutical Industries Ltd.'s Standard Industrial Classification code?
Teva Pharmaceutical Industries Ltd.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 714 words · 3 min read · ~2 pages · Grade level 14.6 · Accepted 2024-04-18 16:06:15
Filing Documents
- d800395d8k.htm (8-K) — 131KB
- d800395dex991.htm (EX-99.1) — 218KB
- 0001193125-24-100771.txt ( ) — 890KB
- teva-20240418.xsd (EX-101.SCH) — 8KB
- teva-20240418_cal.xml (EX-101.CAL) — 1KB
- teva-20240418_def.xml (EX-101.DEF) — 16KB
- teva-20240418_lab.xml (EX-101.LAB) — 32KB
- teva-20240418_pre.xml (EX-101.PRE) — 26KB
- d800395d8k_htm.xml (XML) — 195KB
Financial Statements and Exhibits
Financial Statements and Exhibits (a) Exhibits Exhibit No. Description of Document 99.1
Selected financial data by segment (unaudited)
Selected financial data by segment (unaudited). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: April 1 8 , 2024 By: /s/ Eli Kalif Name: Eli Kalif Title: Executive Vice President, Chief Financial Officer 3